20-347 - BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
Status: openSBESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
Examine the impact of SIGNATERA™ on adjuvant treatment decisions
Contact Us
If you have questions about this trial or are interested in participating, please contact Wendy Blount, director of clinical trials, at (251) 445-9834 or wlblount@health.southalabama.edu.
Description
This study will evaluate how a laboratory test, Signatera, is used to manage care of patients with stage II or III colorectal cancer. Signatera is a laboratory test that uses DNA from a tissue sample to measure circulating tumor (ct)DNA in the blood. The patients enrolled in this study will have Signatera™ ctDNA testing performed as part of their routine care. This is an observational study, which means it will not change the regular medical care patients will receive from their doctor. The study will look at how Signatera™ test results affect patient care decisions and outcomes.
Providers Associated With This Trial
Principle Investigator
![Persing brian]()
View ProfileBrian E. Persing, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology
